Gen Z Woman Survives Gas Explosion, Then She Shares Update 6 Years Later
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
The story of a woman who was caught in a catastrophic gas explosion in Cambodia that left her with second- and third-degree burns over a large part of her body has gone viral on social media.
"I was living there at the time, teaching kindergarten, and had just pulled up to an intersection on a moped when a nearby gas station exploded," 24-year-old Abbey Alexander of Glendive, Montana, told Newsweek. "I suffered second- and third-degree burns across roughly 35 percent of my body, including my arms, legs, and face."
The explosion, which happened on August 14 in 2019, launched Alexander into a yearslong recovery process that she is now chronicling in a memoir. Her story has gained widespread attention after she shared images of her recovery journey in a post on Reddit, marking nearly six years since the incident. The post received more than 163,000 upvotes since being shared on July 20.
From left: Abbey Alexander lays in September 2019 in the burn intensive care unit; and smiles a few days after her bandages were taken off.
From left: Abbey Alexander lays in September 2019 in the burn intensive care unit; and smiles a few days after her bandages were taken off.
Abbey Alexander
"Those photos were taken while I was in the hospital in Denver during my initial recovery," she said.
Approximately 486,000 people in the U.S. are treated each year for burn injuries, noted a November 2024 study published in the Physical Medicine and Rehabilitation Clinics of North America. The study said that "burn injuries are increasingly recognized as causing diverse and dynamic biopsychosocial challenges that can persist throughout survivorship."
Alexander's account aligns with those findings. "It has been intense, both physically and emotionally," she said. "I was initially treated in Cambodian hospitals and eventually medevaced to a burn ICU [intensive care unit] in Denver, where I underwent surgeries and long-term wound care. Since then, I've had to relearn how to walk, manage nerve pain, and work through the trauma of the experience."
Abbey Alexander poses in a car in January this year (left); and during a fishing trip with her baby on the Yellowstone River in Glendive, Montana in May (right).
Abbey Alexander poses in a car in January this year (left); and during a fishing trip with her baby on the Yellowstone River in Glendive, Montana in May (right).
Abbey Alexander
Among the medical interventions Alexander underwent were multiple skin grafts, surgeries and extensive therapy. "I underwent skin grafts, ReCell treatment, multiple debridement surgeries, physical and occupational therapy, compression garment therapy, and ongoing mental health care," she said.
Alexander's early prognosis came with uncertainty. "There were concerns early on about infection, skin-graft rejection, and the risk of long-term disability," she said. "Over time, I've exceeded most expectations, although the emotional recovery has taken longer than the physical."
That emotional toll remains central to her experience. "The invisible scars have been the hardest to manage," Alexander said. "The trauma, PTSD [post-traumatic stress disorder] and emotional toll have lingered the most."
She noted: "Learning to live in a body that has permanently changed, while also holding space for gratitude that I survived, has been an ongoing process."
Do you have a health story to share? Let us know via life@newsweek.com and your story could be featured on Newsweek.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
an hour ago
- Newsweek
Map Shows States Where People Told To Monitor for Coughs, Chest Tightness
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Millions of residents across three states were asked to monitor themselves for health symptoms such as coughing and chest tightness on Monday as poor air quality persisted. Why It Matters Large areas of Maine, Michigan and Vermont faced elevated air pollution levels on Monday, prompting state agencies to issue air quality alerts and health advisories. The warnings, spurred by smoke from ongoing Canadian wildfires, emphasized risks for sensitive groups such as children, the elderly, and those with pre-existing health conditions. The alerts highlighted broader concerns about the impact of wildfire smoke on public health across the U.S. Northeast and Midwest, as similar conditions have become a frequent occurrence this summer due to wildfire patterns. What To Know The Maine Department of Environmental Protection's Bureau of Air Quality issued an alert for particle pollution across the state until 11 p.m. EDT on Monday. The alert covered areas including Oxford, Franklin, Somerset, York, Cumberland, Androscoggin, Kennebec, Waldo and several coastal counties. Officials warned that particle pollution levels were expected to be in the "Unhealthy for Sensitive Groups" range, and recommended people limit strenuous outdoor activity to reduce the risk of adverse health effects. The very young, elderly, people with respiratory conditions such as asthma and heart disease, and those who work hard outdoors, were mentioned as especially vulnerable. Residents experiencing symptoms such as shortness of breath, coughing, throat irritation or chest discomfort were advised to decrease the intensity and duration of outdoor activities. A stock photo shows a man experiencing chest tightness. A stock photo shows a man experiencing chest tightness. Motortion/Getty Similarly, the Michigan Department of Environment, Great Lakes and Energy declared an Air Quality Advisory for Monday across the state, spanning Midland, Bay, Huron, Saginaw, Tuscola, Genesee, Oakland, Washtenaw, Wayne and more. Fine particulate matter (PM2.5) levels were projected to reach "Unhealthy for Sensitive Groups" range, with some locations forecasted to hit the "Unhealthy" range. The advisory urged everyone—particularly those with heart or respiratory illnesses—to avoid strenuous outdoor activities and monitor for symptoms like coughing, chest tightness or wheezing. Additional guidance included keeping windows closed, using filtered air systems and limiting activities contributing to outdoor air pollution such as burning wood. In Vermont, the Vermont Agency of Natural Resources issued an Air Quality Health Advisory warning of fine particulates to hit the Unhealthy for Sensitive Groups range on Monday for Eastern Addison, Eastern Rutland, Eastern Windsor, Orange, Western Addison, Western Rutland and Western Windsor counties in effect through midnight. "Sensitive groups should reduce prolonged or heavy exertion," the alert said. "It's okay to be active outside, but take more breaks and do less intense activities. Watch for symptoms such as coughing or shortness of breath." Several other states across the Upper Midwest and Northeast also had air quality alerts in place, although the alerts didn't specify that people should monitor themselves for symptoms such as coughing or chest tightness. What People Are Saying National Weather Service meteorologist John Boris at the Gaylord, Michigan, office told Newsweek: "Right now, our biggest issue is the fact that there really isn't a whole lot of we get a little bit more flow, there's probably a couple more days of us dealing with this, at least in Michigan." An air quality alert issued in Michigan: "It is recommended that, when possible, you avoid strenuous outdoor activities, especially those with heart disease and respiratory diseases like asthma. Monitor for symptoms such as wheezing, coughing, chest tightness, dizziness, or burning in nose, throat, and eyes." What Happens Next The advisories in Maine, Michigan and Vermont were expected to remain in effect through Monday night, with potential for extension depending on smoke migration and weather conditions. Officials continue to urge residents to track air quality forecasts through official resources, heed recommendations for health precautions, and reduce activities—such as open burning—that exacerbate air pollution.
Newsweek
an hour ago
- Newsweek
PTSD Drug Discovery May Help Patients Let Go of Trauma
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A promising new drug could help people living with post-traumatic stress disorder (PTSD) finally let go of trauma. This is the discovery of scientists at the Institute of Basic Science (IBS) and Ewha Womans University in South Korea who have identified a new brain mechanism driving the mental health condition—and a drug with the potential to counteract its effects. The team has shown for the first time that "excessive" gamma-aminobutyric acid (GABA)—the brain's primary neurotransmitter—produced by star-shaped support cells in the brain known as "astrocytes" impairs the brain's ability to extinguish fear memories. This inability to forget traumatic memories even after a long period of time is distinct to PTSD and has posed a major hurdle for treatment. Current medications targeting serotonin receptors offer limited relief for only a subset of patients, the authors said. "Current FDA-approved treatments for PTSD are mainly SSRIs, which focus on reducing general symptoms like anxiety and mood instability," study author Dr. Woojin Won told Newsweek. "However, only about 20–30 percent of patients achieve full remission, which is often unsatisfactory. Our approach is fundamentally different." Woman with head in hands in dark room. Woman with head in hands in dark room. Domepitipat/Getty Images Won continued: "While prefrontal cortex (PFC) dysfunction has been consistently reported in PTSD, the role of GABAergic mechanisms in this dysfunction has not been fully explored." The researchers found that a brain-permeable drug called KDS2010, which selectively blocks an enzyme called 'monoamine oxidase B' (MAOB) responsible for this abnormal GABA production, can reverse PTSD-like symptoms in mice. "It targets the pathological reactive astrocyte-derived GABA at the source," said Won. "Unlike traditional MAO inhibitors, which can have off-target effects and are irreversible, KDS2010 is highly selective, reversible, and brain-penetrant, making it safer and more targeted." They report the drug has already passed Phase 1 safety trials in humans, which makes it a "strong candidate" for future PTSD treatments. GABA can be a positive thing, helping to regulate motor function, sensory processing and emotional stability. It can also offer calming effects, including helping to reduce anxiety and stress by controlling overactive neurons. "However," Won explained, "GABA does not act uniformly across the brain, and its outcome varies depending on the target circuit. "While GABA is generally calming, in this context [of the researcher's findings], it was silencing a circuit that the brain needs to overcome fear. This highlights that the effect of GABA is not simply good or bad, but it critically depends on where it acts and what neural circuits are involved." Digital illustration showing brain waves and activity. Digital illustration showing brain waves and activity. selvanegra/Getty Images The study focused on the medial prefrontal cortex (mPFC), a region of the brain critical for regulating fear. It found that PTSD patients had unusually high levels of GABA and reduced cerebral blood flow in this area, based on brain imaging studies of more than 380 participants. On the other hand, GABA levels decreased in patients who showed clinical improvement, suggesting the chemical has a central role in recovery. To unearth the origin of the excess GABA, the researchers examined postmortem human brain tissue and used PTSD-like mouse models. They discovered that astrocytes, not neurons, were producing abnormal amounts of GABA via the MAOB enzyme. This astrocyte-derived GABA impaired neural activity, blocking the brain's ability to forget traumatic memories. "This inspired us to investigate astrocytic GABA dysregulation as a potential driver of PTSD pathology, and ultimately, as a novel therapeutic target," said Won. Explaining further how "excessive" GABA in PTSD is produced, he added: "Trauma and stress might increase putrescine metabolism, which raises the levels of MAOB's presubstrate, leading to more GABA production. "At the same time, the enzyme that breaks down GABA, ABAT, is reduced. Together, this combination causes the accumulation of astrocytic GABA and excessive tonic inhibition in key brain regions like the PFC." When the team administered KDS2010, "a highly selective, reversible MAOB inhibitor" developed at IBS, the mice showed normalized brain activity and were able to extinguish fear responses. The promising drug reduced GABA levels, restored blood flow in the mPFC, and re-enabled memory extinction mechanisms. This confirms astrocytic MAOB as a central driver of PTSD symptoms and MAOB inhibition as a viable therapeutic path. The researchers flagged a major challenge of the study was linking clinical findings in humans with cellular mechanisms in the lab. They addressed this by applying a "reverse translational" strategy, beginning with clinical brain scans and moving backward to identify the cellular source of dysfunction. They then confirmed the mechanism and tested drug effects in animal models. This led to a new understanding of how glial cells—non-neuronal cells long thought to be passive—actively shape psychiatric symptoms. Would this type of drug be used alongside other methods like talking therapy for PTSD? "DS2010 alone has a strong potential to restore brain function by normalizing astrocytic GABA and improving fear extinction. However, we think that combining it with psychotherapy, especially exposure-based therapy, could create even greater synergy. By reducing abnormal inhibition in fear extinction circuits, KDS2010 may help the brain become more responsive to therapeutic input," Won explained. How would it be administered? "KDS2010 is an orally available small molecule. In preclinical and early-phase clinical studies, it has been administered once daily in capsule or liquid form. This makes it highly feasible for long-term outpatient use, similar to antidepressants." What about side effects? "In the Phase 1 clinical trial, KDS2010 was found to be well tolerated, with no serious adverse effects reported, even at higher doses. This safety is largely due to its selectivity for MAOB and its reversible mechanism, which avoids the long-term enzyme compensation seen with older MAO inhibitors. Nevertheless, larger trials in PTSD patients will be needed to fully assess tolerability and any rare side effects." Won said the drug is currently undergoing Phase 2 trials for other neurological disorders, which means its safety profile is already being tested extensively in patients. "Because of this, we believe it could reach the public faster than many other new drugs. If future trials for PTSD are successful and regulatory steps proceed smoothly, it could become available within a few years. Importantly, KDS2010 is part of a broader platform that may also be useful for treating other disorders involving astrocytic dysfunction, such as Parkinson's and Alzheimer's disease." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about PTSD? Let us know via health@ Reference Yoon, S., Won, W., Lee, S., Han, K., Ha, E., Lee, J., Hyeon, S. J., Joo, Y., Hong, H., Lee, H., Song, Y., Park, K. D., Huber, B. R., Lee, J., Edden, R. A. E., Suh, M., Ryu, H., Lee, C. J., & Lyoo, I. K. (2025). Astrocytic gamma-aminobutyric acid dysregulation as a therapeutic target for posttraumatic stress disorder. Signal Transduction and Targeted Therapy, 10(1), 240.
Newsweek
an hour ago
- Newsweek
Nearly 17 Million Young Americans Could Benefit From Ozempic-like Drugs
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Nearly 17 million young Americans could be eligible for GLP-1RAs—a class of medications used to treat type 2 diabetes and obesity—including Ozempic and Wegovy. This is based on estimations from Yale School of Medicine researchers who have assessed how many adolescents and young adults in the US are eligible for the drugs and how many can realistically access them. Despite millions being eligible, one in five young adults who meet the criteria are uninsured and one-third denied having a routine place for healthcare. The researchers describe this as "a barrier to identifying, treating, and preventing cardio-kidney-metabolic diseases". The prevalence of type 2 diabetes and obesity continues to increase in youth across the country, hence the need for improved intervention. "Assuming that all individuals who were appropriate candidates for these medications could receive them after shared-decision making with their clinician, we could see substantial progress made in treating and preventing obesity-related diseases in US youth, such as dyslipidemia and hypertension," paper author Ashwin K. Chetty told Newsweek. This, he explained, "could lead to the prevention of severe complications of obesity into adulthood, such as strokes and heart attacks." Hand holding Ozempic-like injection pens on dark background. Hand holding Ozempic-like injection pens on dark said the GLP-1RA eligibility criteria they used covered indications for semaglutide (Ozempic, Rybelsus and Wegovy), liraglutide (Saxenda and Victoza), Bydureon BCise (exenatide), Trulicity (dulaglutide) and tirzepatide (Zepbound and Mounjaro). While some medications contain the same ingredient under a different brand name, the drugs are licensed in different ways. In the U.S., Ozempic, for example, is approved for use in people with type 2 diabetes, while Wegovy is approved for those with obesity or who are overweight and have related health problems. Wegovy and Ozempic mimic a hormone called glucagon-like peptide-1—hence 'GLP-1'—which targets areas of the brain that regulate appetite. "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are approved to treat pediatric obesity and T2D, and a small but growing number of adolescents and young adults receive GLP-1RAs, which are largely covered through private insurance or Medicaid," the researchers wrote. "Insurance status, access to care and clinical profile of the broader population of youth eligible for GLP-1RAs are unclear but important for policy development. We characterized demographic, clinical, and socioeconomic characteristics of US adolescents and young adults eligible for any GLP-1RA." To inform the estimations, the cross-sectional study pooled publicly available data from the National Health and Nutrition Examination Survey (NHANES) January 2017–March 2020 and August 2021–August 2023. They included US adolescents aged 12–17 and young adults aged 18–25 who met U.S. Food and Drug Administration criteria for GLP-1RA treatment. Over-the-shoulder view of a person in bed checking a smartphone. Over-the-shoulder view of a person in bed checking a adolescents, GLP-1RA indications included type 2 diabetes or obesity defined either as BMI in the 95th percentile or higher for age and sex or body weight greater than 60kg and BMI corresponding to 30 for adults by international cutoffs. For young adults, GLP-1RA indications included type 2 diabetes, obesity (a BMI greater than 30) or a BMI of 27 or higher with a weight-related condition (dyslipidemia, hypertension, cardiovascular disease, or type 2 diabetes). The sample included 572 adolescents and 590 young adults eligible for GLP-1RA treatment, representing an estimated 5.8 million adolescents and 11.1 million young adults. Adolescents eligible for the drugs included 40.3 percent insured by Medicaid, 40.5 percent privately insured and 7.2 percent uninsured. Eligible young adults included 20.8 percent insured by Medicaid, 49 percent privately insured and 19.4 percent uninsured. While 92.2 percent of adolescents reported having a routine place for healthcare, 68.1 percent of young adults reported the same, according to the study. Among both groups, cardio-kidney-metabolic risk factors (dyslipidemia, impaired kidney function, hypertension and prediabetes) were prevalent. "Of note, some indications for young adults were fully encompassed by other indications and were not analyzed separately," said Chetty. For example, the indication of type 2 diabetes may include having also a cardiovascular disease. The analysis also did not include people aged 10–11 years with type 2 diabetes as there were too few participants in their sample in that age group with the condition. "While Medicare is not allowed to cover anti-obesity medications that are indicated only for obesity, Medicaid can cover anti-obesity medications, though only a fraction of state Medicaid programs do," said Chetty. The researchers say their findings indicate broad Medicaid coverage could increase access to GLP-1RAs for a large portion of U.S. youth who may benefit from them. "This could look like state-level formulary changes that include anti-obesity medications or federal policy changes that foster coverage for these therapies," said Chetty. "Beyond expanding insurance coverage, improving access also involves ensuring these individuals have access to general healthcare and clinician appointments, which we show in this study is a particularly significant concern for young adults." Why are we seeing rising rates of metabolic diseases in America's youth? Paper author and pediatric nephrologist Dr. James Nugent told Newsweek: "Changes in lifestyle behaviors and structural factors like increased screen time, decreased physical activity, poor sleep, and consumption of ultra-processed foods and sugar-sweetened beverages are important contributors to obesity in youth. "The COVID-19 pandemic has further accelerated the rise in obesity due to its effect on these lifestyle behaviors. Chronic stress, food insecurity, poverty, and adverse childhood experiences are also strongly associated with obesity in youth. Additionally, in utero exposure to maternal obesity and diabetes are risk factors for obesity and type 2 diabetes in childhood." The authors said study limitations include self-reported data subject to recall bias and potential misclassification of the type of diabetes. They also flagged GLP-1RAs should be considered alongside intensive health behavior and lifestyle treatment (and surgery where applicable). And while expanded insurance coverage may substantially increase access, uninsurance and lack of routine care are barriers to this therapy. How can we ensure young people receive holistic care too? "Improving access to comprehensive obesity treatment will involve ensuring that individuals receive access to healthcare with regular follow-ups and support to engage in health behavior and lifestyle treatment, such as specific programs tailored to providing intensive health behavior and lifestyle treatment," said Chetty. "As Dr. Mona Sharifi, a co-author of this paper, has shown, intensive health behavior and lifestyle treatment programs can be cost-effective but inadequate funding is the main barrier to implementing and sustaining these programs." What's next? "Given the size and clinical characteristics of the U.S. youth population eligible for GLP-1RAs, there should be greater discussion of how to improve access to GLP-1RAs and other anti-obesity interventions among this population." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about GLP-1 drugs? Let us know via health@ Reference Chetty, A. K., Sharifi, M., & Nugent, J. T. (2025). Glucagon-like peptide-1 receptor agonist eligibility among US adolescents and young adults. JAMA Pediatrics.
